 The UK government is partnering with BioNTech to enrol up to 10,000 patients in clinical trials for advanced cancer treatments, according to the Financial Times, BioNTech, which developed the best-selling Covid-19 vaccine in partnership with Pfizer, will open a research and development centre in Cambridge, employing 75 staff, as well as an office in London, the paper said. The company is working on personalised cancer vaccines that aim to utilise patients immune systems to fight tumours, and may also potentially invest in manufacturing in the UK in the future. 